Literature DB >> 15326620

Five years of molecular diagnosis of Fragile X syndrome (1997-2001): a collaborative study reporting 95% of the activity in France.

Valérie Biancalana1, Chérif Beldjord, Agnès Taillandier, Sylvie Szpiro-Tapia, Véronica Cusin, Fabienne Gerson, Christophe Philippe, Jean-Louis Mandel.   

Abstract

The Fragile X syndrome is the most common cause of inherited mental retardation. Clinical features are neither specific nor constant and molecular diagnosis is thus widely used since the characterization of the causal mutation in 1991. The aim of this project was to study the evolution of Fragile X diagnosis in France. A preliminary study of the efficiency of screening for the Fragile X mutation in mentally retarded probands with no previous familial diagnosis was done in the Strasbourg's laboratory with a comparison between data from 1991-1994 and 1997-2000. This study showed an improvement in the use of the Fragile X testing regarding the probands' age at diagnosis and the recruitment of sporadic and female cases. To avoid possible bias in clinical referrals and to evaluate the situation nation wide, this study was enlarged to 28 of the 30 laboratories involved in the Fragile X diagnosis in France from 1997 to 2001 (20,816 probands tested, data representative of 95% of the national screening activity). Median age at diagnosis decreased from 9.2 to 5.8 (average 16-11.6y) between the 1991-1994 and the 1997-2001 studies. Over this period, 477 new families were diagnosed with Fragile X, representing 2.8% of tested male probands (417/14,867) and 1.0% of tested female probands (60/5,949). Forty one percent of positive cases corresponded to probands with a familial history of mental retardation, compared to 66% in the initial (1991-1994) study. We also discuss issues concerning premutations discovered in affected individuals and in females with premature ovarian failure (POF).

Entities:  

Mesh:

Year:  2004        PMID: 15326620     DOI: 10.1002/ajmg.a.30237

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  17 in total

1.  Comparative frequency of fragile-X (FMR1) and creatine transporter (SLC6A8) mutations in X-linked mental retardation.

Authors:  J L Mandel
Journal:  Am J Hum Genet       Date:  2004-10       Impact factor: 11.025

2.  XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing.

Authors:  Amélie Piton; Claire Redin; Jean-Louis Mandel
Journal:  Am J Hum Genet       Date:  2013-07-18       Impact factor: 11.025

3.  FMR1 gene mutations in patients with fragile X syndrome and obligate carriers: 30 years of experience in Chile.

Authors:  Lorena Santa María; Solange Aliaga; Víctor Faundes; Paulina Morales; Ángela Pugin; Bianca Curotto; Paula Soto; M Ignacia Peña; Isabel Salas; M Angélica Alliende
Journal:  Genet Res (Camb)       Date:  2016-06-28       Impact factor: 1.588

4.  The fragile x mental retardation syndrome 20 years after the FMR1 gene discovery: an expanding universe of knowledge.

Authors:  François Rousseau; Yves Labelle; Johanne Bussières; Carmen Lindsay
Journal:  Clin Biochem Rev       Date:  2011-08

5.  UBE2A, which encodes a ubiquitin-conjugating enzyme, is mutated in a novel X-linked mental retardation syndrome.

Authors:  Rafaella M P Nascimento; Paulo A Otto; Arjan P M de Brouwer; Angela M Vianna-Morgante
Journal:  Am J Hum Genet       Date:  2006-07-03       Impact factor: 11.025

Review 6.  MECP2 mutations in males.

Authors:  Laurent Villard
Journal:  J Med Genet       Date:  2007-03-09       Impact factor: 6.318

7.  Identification of expanded alleles of the FMR1 Gene in the CHildhood Autism Risks from Genes and Environment (CHARGE) study.

Authors:  Flora Tassone; Nimrah S Choudhary; Federica Tassone; Blythe Durbin-Johnson; Robin Hansen; Irva Hertz-Picciotto; Isaac Pessah
Journal:  J Autism Dev Disord       Date:  2013-03

8.  Clinical utility gene card for: fragile X mental retardation syndrome, fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency.

Authors:  Sebastien Jacquemont; Stefanie Birnbaum; Silke Redler; Peter Steinbach; Valérie Biancalana
Journal:  Eur J Hum Genet       Date:  2011-05-04       Impact factor: 4.246

9.  A pseudo-full mutation identified in fragile X assay reveals a novel base change abolishing an EcoRI restriction site.

Authors:  Shujian Liang; Harold N Bass; Hanlin Gao; Caroline Astbury; Mehdi R Jamehdor; Yong Qu
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

10.  Disease-causing variants in TCF4 are a frequent cause of intellectual disability: lessons from large-scale sequencing approaches in diagnosis.

Authors:  Laura Mary; Amélie Piton; Elise Schaefer; Francesca Mattioli; Elsa Nourisson; Claire Feger; Claire Redin; Magali Barth; Salima El Chehadeh; Estelle Colin; Christine Coubes; Laurence Faivre; Elisabeth Flori; David Geneviève; Yline Capri; Laurence Perrin; Jennifer Fabre-Teste; Dana Timbolschi; Alain Verloes; Robert Olaso; Anne Boland; Jean-François Deleuze; Jean-Louis Mandel; Bénédicte Gerard; Irina Giurgea
Journal:  Eur J Hum Genet       Date:  2018-04-26       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.